These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9382967)

  • 21. Interrelationship between atrial natriuretic peptide and plasma renin, aldosterone and catecholamines in hepatic cirrhosis: the effect of passive leg rising.
    Burghardt W; Müller R; Diehl KL; Wernze H
    Z Kardiol; 1988; 77 Suppl 2():104-10. PubMed ID: 2970163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma endothelin levels in cirrhotic patients and their correlation with atrial natriuretic peptide.
    Chen YX; Wang SC; Zhao GN; Tang J; Zhang SX; Tang CS
    Chin Med J (Engl); 1993 Sep; 106(9):643-6. PubMed ID: 8287696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosine monophosphate production in preascitic cirrhosis.
    Iwao T; Oho K; Nakano R; Sakai T; Sato M; Miyamoto Y; Kumamoto M; Sakai K; Sata M; Toyonaga A
    J Hepatol; 2000 Mar; 32(3):426-33. PubMed ID: 10735612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome.
    Esteva-Font C; Baccaro ME; Fernández-Llama P; Sans L; Guevara M; Ars E; Jiménez W; Arroyo V; Ballarín JA; Ginès P
    Hepatology; 2006 Dec; 44(6):1555-63. PubMed ID: 17133493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites.
    Dussaule JC; Grangé JD; Wolf JP; Lecomte JM; Gros C; Schwartz JC; Bodin F; Ardaillou R
    J Clin Endocrinol Metab; 1991 Mar; 72(3):653-9. PubMed ID: 1847706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of increased plasma adrenomedullin concentration in patients with cirrhosis.
    Kojima H; Tsujimoto T; Uemura M; Takaya A; Okamoto S; Ueda S; Nishio K; Miyamoto S; Kubo A; Minamino N; Kangawa K; Matsuo H; Fukui H
    J Hepatol; 1998 May; 28(5):840-6. PubMed ID: 9625320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial.
    Israelsen M; Dahl EK; Madsen BS; Wiese S; Bendtsen F; Møller S; Fialla AD; Jensen BL; Krag A
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G313-G321. PubMed ID: 31841026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypotension and renal impairment during infusion of atrial natriuretic factor in liver cirrhosis with ascites.
    Ferrier C; Beretta-Piccoli C; Weidmann P; Gnädinger MP; Shaw S; Suchecka-Rachon K; Saxenhofer H
    Am J Nephrol; 1989; 9(4):291-9. PubMed ID: 2530903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems.
    Guevara M; Ginès P; Jiménez W; Sort P; Fernández-Esparrach G; Escorsell A; Bataller R; Bosch J; Arroyo V; Rivera F; Rodés J
    Gastroenterology; 1998 Feb; 114(2):336-43. PubMed ID: 9453495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of endothelins to volume regulating neurohumoral systems in patients with cirrhosis of the liver.
    Gülberg V; Gerbes AL
    Eur J Clin Invest; 1995 Dec; 25(12):893-8. PubMed ID: 8719927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma human atrial natriuretic peptide levels in patients with liver cirrhosis.
    Uemura K; Oguchi H; Kiyosawa K; Furuta S
    J Gastroenterol Hepatol; 1989; 4(2):167-74. PubMed ID: 2535228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis.
    Hendrickse MT; Triger DR
    Am J Gastroenterol; 1994 May; 89(5):750-7. PubMed ID: 8172151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure.
    Gülberg V; Møller S; Henriksen JH; Gerbes AL
    Gut; 2000 Dec; 47(6):852-7. PubMed ID: 11076886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in plasma endothelin-1 and Big endothelin-1 induced by transjugular intrahepatic portosystemic shunts in patients with cirrhosis and refractory ascites.
    Martinet JP; Legault L; Cernacek P; Roy L; Dufresne MP; Spahr L; Fenyves D; Pomier-Layrargues G
    J Hepatol; 1996 Nov; 25(5):700-6. PubMed ID: 8938548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressor systems and urinary sodium excretion.
    Fernández-Rodriguez CM; Prieto J; Quiroga J; Zozoya JM; Andrade A; Núñez M; Sangro B; Penas J
    Hepatology; 1995 Jan; 21(1):35-40. PubMed ID: 7528711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormal sympathetic and renal response to sodium restriction in compensated cirrhosis.
    Simón MA; Díez J; Prieto J
    Gastroenterology; 1991 Nov; 101(5):1354-60. PubMed ID: 1936807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites.
    Wong W; Liu P; Blendis L; Wong F
    Am J Med; 1999 Mar; 106(3):315-22. PubMed ID: 10190381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Renal tubular function in cirrhotic patients with ascites: special reference to lithium clearance following the human atrial natriuretic peptide administration].
    Ando M
    Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):791-801. PubMed ID: 1837568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites.
    Laffi G; Pinzani M; Meacci E; La Villa G; Renzi D; Baldi E; Cominelli F; Marra F; Gentilini P
    Gastroenterology; 1989 Jan; 96(1):167-77. PubMed ID: 2535828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.